Table 2 SPHK1 and S1P inhibitors in clinical development as anti-cancer therapies
| Agent | Mechanism | Stage of Clinical Development | References |
|---|---|---|---|
| Safingol | SPHK1 inhibitor | Demonstrated safety in combination with cisplatin in Phase I trial in solid tumours | [43, 46, 47] |
| Fingolimod | S1P receptor antagonist | Licenced for use in multiple sclerosis. No data on clinical use in cancer | [29, 30, 44] |
| (FTY720) | |||
| Sonepcizumab | Humanised S1P neutralising monoclonal antibody | Demonstrated safety in Phase I trial in solid tumours | [48, 49] |
| (LT1009) |